Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors

NCT07583654 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

mRNA Vaccine
Solid Tumor Cancer
Peptides
Cancer Metastatic

Interventions

BIOLOGICAL: CP-IL22BP mRNA intratumorally injection

Sponsor

West China Hospital